Open AccessLudartin treatment exhibits promising inhibitory effect on the epithelial ovarian cancer growth and metastasis
Author(s) -
Lin Bai,
Hui Wang,
Luo-Ying Zhang,
Aihua Wang,
Jie Bai
Publication year - 2016
Publication title -
bangladesh journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.385
H-Index - 23
eISSN - 1991-0088
pISSN - 1991-007X
DOI - 10.3329/bjp.v11i3.26692
Subject(s) - viability assay , western blot , cell growth , ovarian cancer , metastasis , mtt assay , andrology , cell , gentamicin protection assay , cell migration , medicine , cancer research , chemistry , cancer , biochemistry , gene
In the present study, the effect of ludartin on OVCAR5 ovarian carcinoma cells was investigated. MTT cell assay was used for the analysis of cell viability and wound healing assay for migration potential. Results revealed that ludartin treatment at 10 and 30 µM doses reduced the cell viability from 94 to 38%. The invasive potential was decreased from 62 to 24% with increase in ludartin concentration from 10 to 30 µM. Western blot analysis showed that ludartin treatment reduced the expression of p-FAK in OVCAR5 cells significantly. Ludartin treatment for 48 hours also caused a significant decrease in the expression of MMP-2 and MMP-9 in OVCAR5 cells at a concentration of 30 µM. The metastatic regions were absent in the rats treated with 30 µM/kg doses of ludartin daily for 15 days. Thus, ludartin treatment inhibits the proliferation, invasion and migration of ovarian cancer cells through down-regulation of pFAK and MMPs, therefore can be used for the treatment of ovarian cancer